| Literature DB >> 35737832 |
Yu-Wei Zhou1, Jie Sun1,2, Ye Wang1, Cai-Ping Chen1, Tao Tao1, Ming Ma3, Xin Chen1, Xue-Na Zhang1, Li-Yuan Yang3, Zhong-Liang Zhang3, Ye-Qiong Li1, Zhi-Hui Jiang1, Tian-Tian Qiu1, Han Wang1, Yang Pan4, Jian Zhang5, Hua-Qun Chen2, Pei Wang1, Min-Sheng Zhu1.
Abstract
Both chronic obstructive pulmonary disease (COPD) and asthma are severe respiratory diseases. Bitter receptor-mediated bronchodilation is a potential therapy for asthma, but the mechanism underlying the agonistic relaxation of airway smooth muscle (ASM) is not well defined. By exploring the ASM relaxation mechanism of bitter substances, we observed that pretreatment with the bitter substances nearly abolished the methacholine (MCh)-induced increase in the ASM cell (ASMC) calcium concentration, thereby suppressing the calcium-induced contraction release. The ASM relaxation was significantly inhibited by simultaneous deletion of three Gαt proteins, suggesting an interaction between Tas2R and AChR signaling cascades in the relaxation process. Biochemically, the Gαt released by Tas2R activation complexes with AChR and blocks the Gαq cycling of AChR signal transduction. More importantly, a bitter substance, kudinoside A, not only attenuates airway constriction but also significantly inhibits pulmonary inflammation and tissue remodeling in COPD rats, indicating its modulation of additional Gαq-associated pathological processes. Thus, our results suggest that Tas2R activation may be an ideal strategy for halting multiple pathological processes of COPD.Entities:
Keywords: COPD; acetylcholine receptor; asthma; bitter receptor
Mesh:
Substances:
Year: 2022 PMID: 35737832 PMCID: PMC9245679 DOI: 10.1073/pnas.2121513119
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 12.779